H.C. Wainwright lowered the firm’s price target on Myomo (MYO) to $5 from $9.50 and keeps a Buy rating on the shares. The firm says that while the company’s Q2 ended well, there are warning signs ahead as Myomo reported that the number of patients added to its pipeline was significantly lower than expected.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYO: